» Articles » PMID: 23878586

Increased Risk of RSV Infection in Children with Down's Syndrome: Clinical Implementation of Prophylaxis in the European Union

Overview
Date 2013 Jul 24
PMID 23878586
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Prospective cohort studies show that Down's syndrome (DS) is an independent risk factor for hospitalization for RSV bronchiolitis. It is unknown whether this observation has been translated into specific management for DS children. The primary goal was to assess the knowledge of healthcare providers in the European Union about RSV infection in DS children and to determine whether it influenced the implementation of prophylaxis. DS caregivers were surveyed using a standardized questionnaire, and country-specific guidelines were obtained. Fifty-three caregivers participated. Thirty-nine (86.7%) had knowledge of the increased risk of severe RSV infection in DS children, and 30 (71.4%) graded that it was important to have a statement on the use of RSV prophylaxis in existing guidelines. Twenty-eight participants had a local DS guideline; hard copies of twelve unique guidelines were obtained. Only one (8.3%) contained a statement on RSV prophylaxis for DS, and five considered such a statement for the next version. Conclusion. Most pediatricians had knowledge that DS children have an increased risk of severe RSV infection. Despite the lack of a specific RSV prophylaxis trial in DS, they felt that a statement on RSV prophylaxis in DS guidelines was important, but this was rarely present in current guidelines.

Citing Articles

Knowledge and Attitudes Regarding Respiratory Syncytial Virus (RSV) Prevention: A Systematic Review.

Gavaruzzi T, Ceccarelli A, Nanni C, Vignali C, Colonnello V, Caserotti M Vaccines (Basel). 2025; 13(2).

PMID: 40006706 PMC: 11861692. DOI: 10.3390/vaccines13020159.


Respiratory Syncytial Virus Infection: Treatments and Clinical Management.

Malik S, Ahmad T, Muhammad K, Waheed Y Vaccines (Basel). 2023; 11(2).

PMID: 36851368 PMC: 9962240. DOI: 10.3390/vaccines11020491.


Respiratory Syncytial Virus-related Death in Children With Down Syndrome: The RSV GOLD Study.

Lowensteyn Y, Phijffer E, Simons J, Scheltema N, Mazur N, Nair H Pediatr Infect Dis J. 2020; 39(8):665-670.

PMID: 32332221 PMC: 7360096. DOI: 10.1097/INF.0000000000002666.


Past, Present and Future Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children.

Simoes E, Bont L, Manzoni P, Fauroux B, Paes B, Figueras-Aloy J Infect Dis Ther. 2018; 7(1):87-120.

PMID: 29470837 PMC: 5840107. DOI: 10.1007/s40121-018-0188-z.


Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection.

Resch B Hum Vaccin Immunother. 2017; 13(9):2138-2149.

PMID: 28605249 PMC: 5612471. DOI: 10.1080/21645515.2017.1337614.


References
1.
Frogel M, Stewart D, Hoopes M, Fernandes A, Mahadevia P . A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis. J Manag Care Pharm. 2010; 16(1):46-58. PMC: 10437841. DOI: 10.18553/jmcp.2010.16.1.46. View

2.
Bloemers B, Marceline van Furth A, Weijerman M, Gemke R, Broers C, van den Ende K . Down syndrome: a novel risk factor for respiratory syncytial virus bronchiolitis--a prospective birth-cohort study. Pediatrics. 2007; 120(4):e1076-81. DOI: 10.1542/peds.2007-0788. View

3.
Eidelman A, Megged O, Feldman R, Toker O . The burden of respiratory syncytial virus bronchiolitis on a pediatric inpatient service. Isr Med Assoc J. 2009; 11(9):533-6. View

4.
Bloemers B, Marceline van Furth A, Weijerman M, Gemke R, Broers C, Kimpen J . High incidence of recurrent wheeze in children with down syndrome with and without previous respiratory syncytial virus lower respiratory tract infection. Pediatr Infect Dis J. 2009; 29(1):39-42. DOI: 10.1097/INF.0b013e3181b34e52. View

5.
Warren A, Langley J, Thomas W, Scott J . Optimizing the delivery and use of a new monoclonal antibody in children with congenital heart disease: a successful provincial respiratory syncytial virus prophylaxis program. Can J Cardiol. 2007; 23(6):463-6. PMC: 2650666. DOI: 10.1016/s0828-282x(07)70785-7. View